Skip to main content

Table 1 Characteristics of CN-AML patients by high and low CPT1a expression

From: Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199

 

CPT1a expression

P-value

LOW expression (N = 80)

High expression (N = 245)

Number (%)

80 (25%)

245 (75%)

 

Male, n (%)

53 (67.1)

137 (56.6)

0.13

Age, median (IQR),years

49.00 (36.00, 61.00)

56.00 (39.75, 65.00)

0.054

BM blast, median (IQR),%

60.00 (29.00, 81.00)

68.00 (43.00, 81.00)

0.179

WBC, median (IQR), ×109/L

14.70 (3.65, 64.68)

10.50 (2.38, 45.98)

0.336

HB, median (IQR), g/L

89.90 (67.75, 105.75)

84.00 (67.75, 102.25)

0.360

PLT, median (IQR),×109/L

45.00 (22.75, 78.00)

49.00 (26.00, 94.75)

0.199

FAB classification, n (%)

  

0.996

 M0

8 (10.0)

22 (9.0)

 

 M1

7 (8.8)

19 (7.8)

 

 M2

39 (48.8)

122 (49.8)

 

 M3

1 (1.2)

3 (1.2)

 

 M4

3 (3.8)

10 (4.1)

 

 M5

20 (25.0)

63 (25.7)

 

 M6

2 (2.5)

4 (1.6)

 

Genes mutations, n (%)

   

 FLT3ITD

11 (14.1)

49 (20.9)

0.190

CEBPADM1

10 (13.9)

30 (13.8)

1

 NPM1

19 (25.0)

63 (28.0)

0.657

 DNMT3A

5 (7.1)

33 (15.8)

0.073

 IDH1

19 (26.0)

42 (20.3)

0.325

 IDH2

7 (10.8)

33 (16.3)

0.323

ELN favorable group, n (%)

   

 Treatment, n (%)2

   

 CPT1A, median (IQR)

0.58 (0.30, 0.78)

2.79 (1.69, 4.66)

 < 0.001

  1. WBC: white blood cell; HB: hemoglobin; PLT: platelet counts; BM: bone marrow; FAB: French–American–British classification systems
  2. 1DM: Double−allele
  3. 2The protocols used for induction therapy in different groups including HAA, homoharringtonine−based treatment (homoharringtonine 2 mg/m2/day for 3 days, cytarabine 75 mg/m2 twice daily for 7 days, aclarubicin 12 mg/m2 daily for 7 days) regimen; DA, daunorubicin 45 mg/m2 daily for 3 days and cytarabine 100 mg/m2 daily for 7 days; IA, idarubicin 6–8 mg/m2 daily for 7 days and aclarubicin 20 mg/m2 daily for 5 days. IQR, interquartile. BMT: bone marrow transplantation. ELN (European leukemia Net) favorable genotype represents NPM1 mutant and FLT3−ITD negative or double allele CEBPA mutations